DIS3L2

Across TCGA pan-cancer cohorts, DIS3L2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DIS3L2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher DIS3L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DIS3L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and SCLC are the cancer types where DIS3L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
UCEC	DFS	Median	All	0.970	0.624	.009	14	view →
SCLC	DFS	Median	II,III,IV	0.178	0.573	.016	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	II,III,IV	0.332	0.664	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DIS3L2–OV (OS)

Open the OV breakdown →